De‐Escalating Surgery for 1–2 cm Appendiceal Neuroendocrine Tumors: A North American Multi‐Center Analysis
Journal of Surgical Oncology · 2026-07 · 134 (1) · 91-100
DOI: 10.1002/jso.70274 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Surgical Oncology, online erschienen am 29.04.2026. Verfasst von Richard Max Miller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Mayo Clinic, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Appendiceal Neoplasms, Neuroendocrine Tumors, Appendectomy, Colectomy. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Mayo Clinic Arizona Department of Surgery.
Abstract (Originalsprache)
Background and Objectives NCCN guidelines recommend right hemicolectomy (RHC) for appendiceal neuroendocrine tumors (aNETs) > 2 cm and observation for < 1 cm. However, optimal surgical management of 1–2 cm tumors remains controversial. This study compared long‐term survival and recurrence between patients undergoing RHC versus appendectomy (APY) for 1–2 cm aNETs.
Methods
Patients with pathologically confirmed 1–2 cm aNETs treated at three Mayo Clinic sites (1972–2024) were included. Primary outcomes were recurrence and all‐cause mortality after resection. Associations with lymph node (LN) metastasis were assessed in patients with lymphadenectomy.
Results
Sixty‐five patients were identified: 29 (45%) underwent APY, 35 (54%) RHC, and one ileocecectomy. Median age at diagnosis was 39 years; 71% were female and 94% white. LN positivity was 15.2% for tumors with nodes examined. Tumor size > 1.5 cm, stage T3/T4, and lymphovascular invasion were not associated with nodal metastasis. No survival differences were observed between APY and RHC. LN positivity did not impact survival. No recurrences occurred during a median follow‐up of 6.25 years (IQR 2.44–12.63).
Conclusions
Among patients with 1–2 cm aNETs, RHC conferred no survival benefit over APY. Absence of recurrence and the limited prognostic value of nodal disease suggest APY alone may suffice for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Mayo Clinic, Phoenix, Arizona, USA.
- Department of Surgery, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Richard Max Miller, Travis E Grotz
Förderung
- Mayo Clinic Arizona Department of Surgery
Zitieren
APA
Miller, R. M., Tan, P. H., Saleeb, A., Thompson, E. R., Fong, Z. V., Stucky, C. C., Bagaria, S. P., Gabriel, E. M., Grotz, T. E., & Wasif, N. (2026). De‐Escalating Surgery for 1–2 cm Appendiceal Neuroendocrine Tumors: A North American Multi‐Center Analysis. Journal of Surgical Oncology, 134(1), 91-100. https://doi.org/10.1002/jso.70274
Vancouver
Miller RM, Tan PH, Saleeb A, Thompson ER, Fong ZV, Stucky CC, et al. De‐Escalating Surgery for 1–2 cm Appendiceal Neuroendocrine Tumors: A North American Multi‐Center Analysis. Journal of Surgical Oncology. 2026;134(1):91-100. doi:10.1002/jso.70274
BibTeX
@article{Miller2026,
author = {Miller, Richard Max and Tan, Po Hong and Saleeb, Andrew and Thompson, Emily R and Fong, Zhi Ven and Stucky, Chee-Chee and Bagaria, Sanjay P and Gabriel, Emmanuel M and Grotz, Travis E and Wasif, Nabil},
title = {De‐Escalating Surgery for 1–2 cm Appendiceal Neuroendocrine Tumors: A North American Multi‐Center Analysis},
journal = {Journal of Surgical Oncology},
year = {2026},
volume = {134},
number = {1},
pages = {91--100},
doi = {10.1002/jso.70274}
}
EUVIMED